Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **fixed-dose combination** of three active pharmaceutical ingredients: **sulfamethoxazole**, an antibacterial sulfonamide; **trimethoprim**, a dihydrofolate reductase inhibitor antibiotic; and **guaifenesin**, an expectorant. The combination is used, particularly in some countries like Peru, for the treatment of **acute bronchitis** and other acute respiratory tract infections. Sulfamethoxazole and trimethoprim act synergistically to inhibit successive steps of bacterial folic acid synthesis, providing bactericidal activity against a broad spectrum of susceptible bacteria. Guaifenesin acts as an expectorant to decrease the viscosity of bronchial secretions, easing productive cough. The use of this combination for acute bronchitis is controversial since most cases are viral, but it remains in routine practice in certain regions and populations[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethoxazole + trimethoprim + guaifenesin.